| abstract |
This application relates to antibodies that bind CSF1R. Antibodies that bind CSF1R are provided. Antibody heavy and light chains capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies against CSF1R are provided. Polynucleotides encoding antibody heavy and light chains are also provided. Methods of treatment using antibodies directed against CSF1R are provided. These methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis. |